Interim CDC guidance: Zika virus exposure testing algorithm *,†,§,** for a pregnant woman residing in an area with active Zika virus transmission ††, with or without clinical illness consistent with Zika virus disease. §§ Updated April 5, 2016.


2. Test for Zika virus infection
   - Contact the Southern Nevada Health District Office of Epidemiology: (702) 759-1300 Option 2 to arrange testing
   - Positive or Inconclusive Result?
     - Consider serial fetal ultrasounds
     - Fetal abnormalities consistent with Zika virus disease^ present?
       - Yes: Retest pregnant woman for Zika virus infection
       - No: Routine prenatal care, Test for Zika Virus infection mid-2^rd trimester, Consider an additional fetal ultrasound

3. Test for Zika virus infection upon initiation of prenatal care
   - Contact the Southern Nevada Health District Office of Epidemiology: (702) 759-1300 Option 2 to arrange testing
   - Positive or Inconclusive Result?
     - Yes: Fetal ultrasound at 18-20 weeks of gestation, Test for Zika virus infection mid-2^nd trimester
     - No: Fetal abnormalities consistent with Zika virus disease^ present or positive or inconclusive test for Zika virus infection?
       - Yes: Fetal abnormalities consistent with Zika virus disease^: consider retesting pregnant women for Zika virus infection
       - No: Routine prenatal care, Consider an additional ultrasound

---

*Tests for pregnant women with clinical illness consistent with Zika virus disease include Zika virus reverse transcription-polymerase chain reaction (RT-PCR), and Zika virus immunoglobulin M (IgM) and neutralizing antibodies on serum specimens [http://www.cdc.gov/zika/pdfs/denvchikvzikv-testing-algorithm.pdf](http://www.cdc.gov/zika/pdfs/denvchikvzikv-testing-algorithm.pdf). Because of the overlap of symptoms and areas where other viral illnesses are endemic, evaluation for dengue or chikungunya virus infection is also recommended. If chikungunya or dengue virus RNA is detected, treat in accordance with existing guidelines. Timely recognition and supportive treatment for dengue virus infections can substantially lower the risk of medical complications and death. Repeat Zika virus testing during pregnancy is warranted if clinical illness consistent with Zika virus disease develops later in pregnancy.

†Testing can be offered to pregnant women without clinical illness consistent with Zika virus disease. If performed, testing should include Zika virus IgM, and if IgM test result is positive or indeterminate, neutralizing antibodies on serum specimens. Results from serologic testing are challenging to interpret in areas where residents have had previous exposure to other flaviviruses (e.g., dengue, yellow fever).

§Laboratory evidence of maternal Zika virus infection: 1) Zika virus RNA detected by RT-PCR in any clinical specimen; or 2) positive Zika virus IgM with confirmatory neutralizing antibody titers that are ≥4-fold higher than dengue virus neutralizing antibody titers. Testing is considered inconclusive if Zika virus neutralizing antibody titers are <4-fold higher than dengue virus neutralizing antibody titers.

**Fetal ultrasounds might not detect microcephaly or intracranial calcifications until the late second or early third trimester of pregnancy.

††Local health officials should determine when to implement testing of asymptomatic pregnant women based on information about levels of Zika virus transmission and laboratory capacity.

§§Clinical illness consistent with Zika virus disease is defined as two or more of the following signs or symptoms: acute onset of fever, maculopapular rash, arthralgia, or conjunctivitis.

^Fetal abnormalities consistent with Zika virus disease include microcephaly, intracranial calcifications, and brain or eye abnormalities until late second or early third trimester of pregnancy.